Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.61 |
| ▸ | MME | P08473 | 2/20 | 0.59 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CPA1 | P15085 | 1/20 | 0.58 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 2/20 | 0.56 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.56 |
| ▸ | ECE1 | P42892 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4182347 | 1.00 | ACE (0.61) | ACEMMEPSMB5L3MBTL1CPA1 | |
| SCHEMBL3704677 | 1.00 | ACE (0.61) | ACEMMEPSMB5L3MBTL1CPA1 | |
| SCHEMBL15692319 | 0.94 | PSMB5 (0.64) | ACEMMEPSMB5CPA1ACE2 | |
| SCHEMBL7901632 | 0.92 | MME (0.66) | ACEMMECPA1ACE2 | |
| SCHEMBL7903892 | 0.92 | MME (0.66) | ACEMMECPA1ACE2 | |
| SCHEMBL17361045 | 0.89 | ACE (0.65) | ACEMMEPSMB5L3MBTL1CPA1 | |
| SCHEMBL27724295 | 0.89 | ACE (0.65) | ACEMMEPSMB5L3MBTL1CPA1 | |
| SCHEMBL29337392 | 0.89 | ACE (0.54) | ACEMMEPSMB5L3MBTL1CPA1 | |
| SCHEMBL8533429 | 0.88 | PSMB5 (0.58) | ACEPSMB5 | |
| SCHEMBL16473192 | 0.88 | ALDH1A1 (0.60) | ACEPSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119350175-A | Novel acyl phenylalanine derivatives, preparation method thereof and application thereof as medicines | 广东药科大学 | 2025-01-24 | — | — | CN | disclosed |
| US-8841309-B2 | Substituted pyrazines and their use in the treatment of disease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-23 | — | — | US | disclosed |
| US-8093231-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | TELIK, INC. | 2008-02-14 | — | — | US | disclosed |
| US-7262182-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-3983162-A | Optical resolution of alkyl esters of DL-phenylalanine | G. D. SEARLE & CO. (US) | 1976-09-28 | — | — | US | disclosed |
| US-3941831-A | Resolution of alkyl esters of DL-phenylalanine | G. D. SEARLE & CO. (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | MTAP, TYMP, PHOSPHO1 | ACE 3043/4885MME 559/4885PSMB5 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.